Pirtobrutinib
August 6, 2024
Pirtobrutinib is approved for the treatment of CLL and SLL in those whose disease has either relapsed or become refractory after having been previously treated
Pirtobrutinib is approved for the treatment of CLL and SLL in those whose disease has either relapsed or become refractory after having been previously treated
Long-term follow-up shows that pirtobrutinib is effective in patients with CLL who have received multiple prior lines of therapy.
The majority of CLL patients who had previously relapsed on covalent BTK inhibitors responded well to pirtobrutinib therapy.
Pirtobrutinib is a useful treatment option to temporarily manage Richter’s transformation, but long-term treatments are still needed.
On Dec. 1, 2023, pirtobrutinib received accelerated approval from the FDA for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients who had failed two prior lines of therapy, including a BTK inhibitor (BTKi) and a BCL-2 inhibitor.
A newly published paper in the New England Journal of Medicine found that pirtobrutinib shows efficacy in patients with heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had received a covalent Bruton tyrosine kinase inhibitor (BTKi).
Pirtobrutinib is a new BTK inhibitor that binds differently (non-covalently) to BTK than the three approved BTK inhibitors, ibrutinib, acalabrutinib, and zanubrutinib.
Pirtobrutinib can extend the benefits of Bruton tyrosine kinase (BTKi) in patients with CLL / SLL who are resistant to covalent BTKi